Menu
Back to User profile » Dr Adam J Savitz
Papers published by Dr Adam J Savitz:
Comparison of Relapse Prevention with 3 Different Paliperidone Formulations in Patients with Schizophrenia Continuing versus Discontinuing Active Antipsychotic Treatment: A Post-Hoc Analysis of 3 Similarly Designed Randomized Studies
Mathews M, Gopal S, Singh A, Nuamah I, Pungor K, Tan W, Soares B, Kim E, Savitz AJ
Neuropsychiatric Disease and Treatment 2020, 16:1533-1542
Published Date: 19 June 2020
Clinical relevance of paliperidone palmitate 3-monthly in treating schizophrenia
Mathews M, Gopal S, Nuamah I, Hargarter L, Savitz AJ, Kim E, Tan W, Soares B, Correll CU
Neuropsychiatric Disease and Treatment 2019, 15:1365-1379
Published Date: 21 May 2019
Predictors of achieving remission in schizophrenia patients treated with paliperidone palmitate 3-month formulation
Nash AI, Turkoz I, Savitz AJ, Mathews M, Kim E
Neuropsychiatric Disease and Treatment 2019, 15:731-737
Published Date: 22 March 2019
Efficacy and safety of paliperidone palmitate 3-month versus 1-month formulation in patients with schizophrenia: comparison between European and non-European population
Savitz AJ, Xu H, Gopal S, Nuamah I, Ravenstijn P, Hough D, Hargarter L
Neuropsychiatric Disease and Treatment 2019, 15:587-602
Published Date: 21 February 2019
Time to onset and time to resolution of extrapyramidal symptoms in patients with exacerbated schizophrenia treated with 3-monthly vs once-monthly paliperidone palmitate
Mathe}ws M, Nuamah I, Savitz AJ, Hough DW, Najarian D, Kim E, Gopal S
Neuropsychiatric Disease and Treatment 2018, 14:2807-2816
Published Date: 25 October 2018
Efficacy and safety of paliperidone palmitate three-monthly formulation in East Asian patients with schizophrenia: subgroup analysis of a global, randomized, double-blind, Phase III, noninferiority study
Savitz AJ, Xu H, Gopal S, Nuamah I, Ravenstijn P, Hough D, Mathews M, Feng Y, Yu L, Takahashi M, Liu D, Wang G, Yoon J, Chen JJ
Neuropsychiatric Disease and Treatment 2017, 13:2193-2207
Published Date: 17 August 2017
Incidence and time course of extrapyramidal symptoms with oral and long-acting injectable paliperidone: a posthoc pooled analysis of seven randomized controlled studies
Gopal S, Liu Y, Alphs L, Savitz A, Nuamah I, Hough D
Neuropsychiatric Disease and Treatment 2013, 9:1381-1392
Published Date: 20 September 2013